Rifaximin in Patients With Diabetic Gastroparesis
| 适应症 | Crohn Disease, Diabetic Gastroparesis |
|---|---|
| 分期 | 2期 |
| 申办方 | Mayo Clinic |
| 状态 | 提前终止 |
| 受试者人数 | 5 人 |
| 干预（药物） | Rifaximin |
| 开始日期 | 2019年6月14日 |
| 完成日期 | 2025年4月8日 |
| 结果公布日 | 2026年6月22日 |
摘要
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
Improvement in Bloating Based on Overall Questionnaire Scoring
| Intervention Treatment | 4 participants |
|---|---|
| Placebo Group | 1 participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Act — Janssen Research & Development, LLC
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severe — Janssen Research & Development, LLC
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn' — Janssen Research & Development, LLC
- A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Partic — Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease — Celularity Incorporated
- Loss of RESponse to Ustekinumab Treated by Dose Escalation — Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW